<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01105130</url>
  </required_header>
  <id_info>
    <org_study_id>REBACCCWFU 98110</org_study_id>
    <secondary_id>U10CA081851</secondary_id>
    <nct_id>NCT01105130</nct_id>
  </id_info>
  <brief_title>L-Arginine Supplementation With or Without Enzyme Inhibitors Treating Erectile Function of Prostate Cancer Survivors</brief_title>
  <official_title>A Randomized Phase II Dose Finding Study of ArginMax for Its Effect on Erectile Function and Quality of Life in Survivors of Prostate Cancer Previously Treated With Radiotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wake Forest University Health Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Wake Forest University Health Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: L-arginine supplements may improve the quality of life and erectile function in
      men who are prostate cancer survivors.

      PURPOSE: This randomized phase II trial is studying how well L-arginine supplementation works
      with or without enzyme inhibitors in treating erectile function and quality of life of
      prostate cancer survivors previously treated with radiation therapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Primary

        -  To determine the &quot;best dose&quot; (defined as the dose that shows the greatest improvement in
           the erectile function domain of the International Index of Erectile Function [IIEF]
           after 8 weeks of therapy) of an L-arginine/Korean ginseng/gingko biloba/damiana-based
           supplement (L-arginine) to be used in a subsequent phase III trial in prostate cancer
           survivors previously treated with radiotherapy.

      Secondary

        -  Evaluate the toxicity of treatment with L-arginine with or without phosphodiesterase-5
           inhibitors.

        -  Estimate trial accrual, retention, adherence, and variability.

        -  Assess changes in quality of life (QOL) and sexual function as defined by changes in the
           QOL of these patients using the Expanded Prostate Cancer Index Composite, changes in the
           other domains of the IIEF (i.e., orgasmic function, sexual desire, intercourse
           satisfaction, and overall satisfaction), changes in the Sexual Encounter Profile, and
           changes in the percentage of &quot;yes&quot; (positive) responses to either of the two global
           efficacy questions.

      OUTLINE: Patients are stratified according to age (&lt; 65 years vs â‰¥ 65 years) and current use
      of phosphodiesterase-5 (PDE-5) inhibitors (yes vs no). Patients are randomized to 1 of 3
      treatment arms.

        -  Arm I: Patients receive oral placebo twice daily (total of 6 capsules per day).

        -  Arm II: Patients receive oral L-arginine and oral placebo twice daily (total of 3
           capsules of each per day).

        -  Arm III: Patients receive oral L-arginine twice daily (total of 6 capsules per day).

      In all arms, treatment continues for 8 weeks in the absence of unacceptable toxicity.

      Patients may also receive oral sildenafil, tadalafil, or vardenafil (PDE-5 inhibitors).

      Patients complete the International Index of Erectile Function and the Expanded Prostate
      Cancer Index Composite-26 at baseline and at weeks 4 and 8. Patients also complete the Sexual
      Encounter Profile Questionnaire, FACT-P, and the Global Efficacy Questionnaire at weeks 4 and
      8.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2010</start_date>
  <completion_date type="Actual">January 2014</completion_date>
  <primary_completion_date type="Actual">January 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Erectile Function</measure>
    <time_frame>8 weeks</time_frame>
    <description>The International Index of Erectile Function (IIEF) questionnaire consists of 15 questions, each of which is scored on a 0 to 5 or 1 to 5 scale. It is comprised of five domains, each scored as the sum of 2 to 5 questions. Erectile function is the sum of six questions with a range from 1 to 30. Higher scores indicate better functioning.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Retention</measure>
    <time_frame>8 weeks</time_frame>
    <description>Retention is the percentage of participants who complete the 8 week visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adherence</measure>
    <time_frame>8 weeks</time_frame>
    <description>Adherence is the percentage of prescribed pills taken by the participants</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life</measure>
    <time_frame>8 weeks</time_frame>
    <description>Quality of life is quantified by the Functional Assessment of Cancer Therapy - Prostate (FACT_P) questionnaire. The FACT questionnaire is comprised of four subscales - social, emotional, functional, and physical. Each subscale is obtained by summing over 6-7 items, each of which is coded on a 0 to 4 scale. Negatively worded questions are reverse scored and higher scores for each subscale indicate better HRQOL. The social, functional, and physical subscales range from 0 to 28 while the emotional subscale ranges from 0 to 24. The overall score (FACT-G) is the sum over the four subscales and ranges from 0 to 108. Patients also completed 12 questions related to prostate cancer, and the prostate subscale score is the sum of those responses (with some items reverse scored). Scores range from 0 to 48, and as with the other FACT subscales higher scores indicate better HRQOL. FACT-P is the sum of FACT-G and the prostate subscale. This questionnaire was added half-way through the study.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">140</enrollment>
  <condition>Male Erectile Disorder</condition>
  <condition>Prostate Cancer</condition>
  <condition>Radiation Toxicity</condition>
  <arm_group>
    <arm_group_label>Arm I - Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients receive oral placebo twice daily (total of 6 capsules per day).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II - low dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive oral L-arginine and oral placebo twice daily (total of 3 capsules of each per day).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm III - high dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral L-arginine twice daily = 6 capsules per day.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Given orally</description>
    <arm_group_label>Arm I - Placebo</arm_group_label>
    <arm_group_label>Arm II - low dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Oral L-Arginine</intervention_name>
    <description>Given orally 3 capsules ArginMax and 3 Placebo capsules</description>
    <arm_group_label>Arm II - low dose</arm_group_label>
    <arm_group_label>Arm III - high dose</arm_group_label>
    <other_name>ArginMax</other_name>
    <other_name>Placebo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Oral L-Arginine</intervention_name>
    <description>Patients will take 6 capsules of ArginMax twice daily</description>
    <arm_group_label>Arm III - high dose</arm_group_label>
    <other_name>ArginMax</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        INCLUSION CRITERIA:

          -  Male prostate cancer survivor previously treated with radiotherapy and who identifies
             himself as concerned with sexual quality of life, including erectile dysfunction.
             (seed implants are eligible)

          -  Had successful sexual activity prior to the commencement of radiotherapy.

          -  Erectile dysfunction, defined as inability to achieve or maintain an erection
             sufficient for satisfactory sexual performance

          -  Interested in sexual activity and agrees to make at least one sexual intercourse
             attempt with a partner every week during the study.

          -  The usage of PDE-5 inhibitors will be voluntary and will serve as a stratification
             factor. Patients taking PDE-5 inhibitors must agree to assume the responsibility for
             the cost of PDE-5 inhibitor treatment during the protocol period (8 week period) as
             this is not covered in the cost of the trial.

          -  Patients currently taking PDE-5 inhibitors sildenafil (ViagraÂ®, Pfizer
             Pharmaceuticals), tadalafil(CialisÂ®, Lilly ICOS, LLC), and vardenafil (LevitraÂ®, Bayer
             Healthcare / Schering Plough Corp.)must agree to take the medication only as
             prescribed by their treating physician.

          -  Patients taking PDE-5 inhibitors as part of this study must be on a stable dose of
             drug for at least one month prior to study entry.

          -  Must be able to take oral medications.

          -  &gt; 6 months following completion of all cancer therapy

          -  No evidence of prostate cancer

          -  Prior malignancies allowed if no evidence of recurrent disease.

          -  If previously taken LHRH agonist androgen suppression (e.g, Lupron, Zoladex),
             anti-androgen (e.g., Casodex, Eulexin, Nilandron), or estrogenic (e.g.,
             diethylstilbestrol) agents, serum testosterone must have returned to the laboratory
             normal range

          -  No planned surgery while on protocol or for 4 weeks following completion of protocol

          -  Prior cystoscopy is permitted.

          -  Age &gt; 18

          -  ECOG performance status 0/1.

          -  Patients must agree not to start taking an herbal product for erectile dysfunction
             during the eight weeks of study intervention.

        EXCLUSION CRITERIA:

          -  No other concurrent erectile dysfunction therapies permitted (i.e. vacuum
             pump,cavernosal injections, and other drug therapies). Past use of these and other
             therapies permitted if the patient can meet the inclusion criteria above.

          -  No testosterone supplementation permitted.

          -  Use of LHRH agonist androgen suppression (e.g, Lupron, Zoladex), anti- androgen (e.g.,
             Casodex,Eulexin, Nilandron), or estrogenic (e.g., diethylstilbestrol) agents within
             the last 6 months.

          -  Prior prostate or lower genitourinary surgery (bladder, penis, urethra,
             testicles)including transurethral resection of prostate (TURP). (Prior vasectomy is
             allowed)

          -  Serious cardiovascular disease (unstable angina, supraventricular arrhythmia,
             myocardial infarction, symptomatic congestive heart failure, cardiac arrhythmia,
             coronary artery bypass surgery within 6 months prior to registration).

          -  Hypotension (&lt;90/50mm Hg), or uncontrolled hypertension (&gt;170/100 mm Hg)

          -  Stroke or spinal cord injury within 6 months before registration.

          -  Patients on Persantine, heparin, Lovenox, warfarin, ginkgo biloba, Plavix, Disalcid,
             other blood-thinning medication or with a history of bleeding disorders will be
             excluded.(Aspirin &lt; 325mg allowed)

          -  Current use of cimetidine, ketoconazole, itraconazole, erythromycin, or ritonavir.
             Major medical or psychiatric illness which, in the opinion of the investigator, would
             prevent completion of treatment or would interfere with follow-up.

          -  Current or prior use of any organic nitrate within the last 6 months (e.g., use of
             nitroglycerin)

          -  May not receive other investigational agents or devices during 30 days prior to start
             of study drug.

          -  History of allergic reactions attributed to compounds of similar chemical or biologic
             composition to ArginMax (l-arginine, ginseng, or ginkgo biloba)
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James J. Urbanic, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Wake Forest University Health Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>W F Baptist Health</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 14, 2010</study_first_submitted>
  <study_first_submitted_qc>April 14, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 16, 2010</study_first_posted>
  <results_first_submitted>January 12, 2015</results_first_submitted>
  <results_first_submitted_qc>July 15, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 21, 2015</results_first_posted>
  <last_update_submitted>May 25, 2017</last_update_submitted>
  <last_update_submitted_qc>May 25, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 20, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>radiation toxicity</keyword>
  <keyword>male erectile disorder</keyword>
  <keyword>prostate cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
    <mesh_term>Radiation Injuries</mesh_term>
    <mesh_term>Erectile Dysfunction</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Arm I - Placebo</title>
          <description>Patients receive oral placebo twice daily (total of 6 capsules per day).
Placebo: Given orally</description>
        </group>
        <group group_id="P2">
          <title>Arm II - Low Dose</title>
          <description>Patients receive oral L-arginine and oral placebo twice daily (total of 3 capsules of each per day).
Placebo: Given orally
Oral L-Arginine: Given orally 3 capsules ArginMax and 3 Placebo capsules</description>
        </group>
        <group group_id="P3">
          <title>Arm III - High Dose</title>
          <description>Oral L-arginine twice daily = 6 capsules per day.
Oral L-Arginine: Given orally 3 capsules ArginMax and 3 Placebo capsules
Oral L-Arginine: Patients will take 6 capsules of ArginMax twice daily</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="48"/>
                <participants group_id="P2" count="45"/>
                <participants group_id="P3" count="47"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="38"/>
                <participants group_id="P2" count="34"/>
                <participants group_id="P3" count="37"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="10"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Never Started</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Toxicity</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Multiple Reasons</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All randomized participants</population>
      <group_list>
        <group group_id="B1">
          <title>Arm I - Placebo</title>
          <description>Patients receive oral placebo twice daily (total of 6 capsules per day).
Placebo: Given orally</description>
        </group>
        <group group_id="B2">
          <title>Arm II - Low Dose</title>
          <description>Patients receive oral L-arginine and oral placebo twice daily (total of 3 capsules of each per day).
Placebo: Given orally
Oral L-Arginine: Given orally 3 capsules ArginMax and 3 Placebo capsules</description>
        </group>
        <group group_id="B3">
          <title>Arm III - High Dose</title>
          <description>Oral L-arginine twice daily = 6 capsules per day.
Oral L-Arginine: Given orally 3 capsules ArginMax and 3 Placebo capsules
Oral L-Arginine: Patients will take 6 capsules of ArginMax twice daily</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="48"/>
            <count group_id="B2" value="45"/>
            <count group_id="B3" value="47"/>
            <count group_id="B4" value="140"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="40"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                    <measurement group_id="B2" value="32"/>
                    <measurement group_id="B3" value="34"/>
                    <measurement group_id="B4" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="68" lower_limit="48" upper_limit="78"/>
                    <measurement group_id="B2" value="68" lower_limit="54" upper_limit="80"/>
                    <measurement group_id="B3" value="67" lower_limit="53" upper_limit="80"/>
                    <measurement group_id="B4" value="68" lower_limit="48" upper_limit="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="48"/>
                    <measurement group_id="B2" value="45"/>
                    <measurement group_id="B3" value="47"/>
                    <measurement group_id="B4" value="140"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                    <measurement group_id="B2" value="43"/>
                    <measurement group_id="B3" value="45"/>
                    <measurement group_id="B4" value="133"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="17"/>
                    <measurement group_id="B4" value="47"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="28"/>
                    <measurement group_id="B4" value="91"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48"/>
                    <measurement group_id="B2" value="45"/>
                    <measurement group_id="B3" value="47"/>
                    <measurement group_id="B4" value="140"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Erectile Function</title>
        <description>The International Index of Erectile Function (IIEF) questionnaire consists of 15 questions, each of which is scored on a 0 to 5 or 1 to 5 scale. It is comprised of five domains, each scored as the sum of 2 to 5 questions. Erectile function is the sum of six questions with a range from 1 to 30. Higher scores indicate better functioning.</description>
        <time_frame>8 weeks</time_frame>
        <population>All participants providing data at any time.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm I - Placebo</title>
            <description>Patients receive oral placebo twice daily (total of 6 capsules per day).
Placebo: Given orally</description>
          </group>
          <group group_id="O2">
            <title>Arm II - Low Dose</title>
            <description>Patients receive oral L-arginine and oral placebo twice daily (total of 3 capsules of each per day).
Placebo: Given orally
Oral L-Arginine: Given orally 3 capsules ArginMax and 3 Placebo capsules</description>
          </group>
          <group group_id="O3">
            <title>Arm III - High Dose</title>
            <description>Oral L-arginine twice daily = 6 capsules per day.
Oral L-Arginine: Given orally 3 capsules ArginMax and 3 Placebo capsules
Oral L-Arginine: Patients will take 6 capsules of ArginMax twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Erectile Function</title>
          <description>The International Index of Erectile Function (IIEF) questionnaire consists of 15 questions, each of which is scored on a 0 to 5 or 1 to 5 scale. It is comprised of five domains, each scored as the sum of 2 to 5 questions. Erectile function is the sum of six questions with a range from 1 to 30. Higher scores indicate better functioning.</description>
          <population>All participants providing data at any time.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="43"/>
                <count group_id="O3" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.62" spread="1.09"/>
                    <measurement group_id="O2" value="14.26" spread="1.13"/>
                    <measurement group_id="O3" value="11.82" spread="1.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Retention</title>
        <description>Retention is the percentage of participants who complete the 8 week visit.</description>
        <time_frame>8 weeks</time_frame>
        <population>All randomized participants</population>
        <group_list>
          <group group_id="O1">
            <title>Arm I - Placebo</title>
            <description>Patients receive oral placebo twice daily (total of 6 capsules per day).
Placebo: Given orally</description>
          </group>
          <group group_id="O2">
            <title>Arm II - Low Dose</title>
            <description>Patients receive oral L-arginine and oral placebo twice daily (total of 3 capsules of each per day).
Placebo: Given orally
Oral L-Arginine: Given orally 3 capsules ArginMax and 3 Placebo capsules</description>
          </group>
          <group group_id="O3">
            <title>Arm III - High Dose</title>
            <description>Oral L-arginine twice daily = 6 capsules per day.
Oral L-Arginine: Given orally 3 capsules ArginMax and 3 Placebo capsules
Oral L-Arginine: Patients will take 6 capsules of ArginMax twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Retention</title>
          <description>Retention is the percentage of participants who complete the 8 week visit.</description>
          <population>All randomized participants</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="45"/>
                <count group_id="O3" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.2" lower_limit="65.0" upper_limit="89.5"/>
                    <measurement group_id="O2" value="75.6" lower_limit="60.5" upper_limit="87.1"/>
                    <measurement group_id="O3" value="78.7" lower_limit="64.3" upper_limit="89.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adherence</title>
        <description>Adherence is the percentage of prescribed pills taken by the participants</description>
        <time_frame>8 weeks</time_frame>
        <population>Participants who returned pill diaries.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm I - Placebo</title>
            <description>Patients receive oral placebo twice daily (total of 6 capsules per day).
Placebo: Given orally</description>
          </group>
          <group group_id="O2">
            <title>Arm II - Low Dose</title>
            <description>Patients receive oral L-arginine and oral placebo twice daily (total of 3 capsules of each per day).
Placebo: Given orally
Oral L-Arginine: Given orally 3 capsules ArginMax and 3 Placebo capsules</description>
          </group>
          <group group_id="O3">
            <title>Arm III - High Dose</title>
            <description>Oral L-arginine twice daily = 6 capsules per day.
Oral L-Arginine: Given orally 3 capsules ArginMax and 3 Placebo capsules
Oral L-Arginine: Patients will take 6 capsules of ArginMax twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Adherence</title>
          <description>Adherence is the percentage of prescribed pills taken by the participants</description>
          <population>Participants who returned pill diaries.</population>
          <units>percentage of prescribed pills</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="41"/>
                <count group_id="O3" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.5" lower_limit="40" upper_limit="100"/>
                    <measurement group_id="O2" value="95.0" lower_limit="50" upper_limit="100"/>
                    <measurement group_id="O3" value="95.0" lower_limit="36" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quality of Life</title>
        <description>Quality of life is quantified by the Functional Assessment of Cancer Therapy - Prostate (FACT_P) questionnaire. The FACT questionnaire is comprised of four subscales â€“ social, emotional, functional, and physical. Each subscale is obtained by summing over 6-7 items, each of which is coded on a 0 to 4 scale. Negatively worded questions are reverse scored and higher scores for each subscale indicate better HRQOL. The social, functional, and physical subscales range from 0 to 28 while the emotional subscale ranges from 0 to 24. The overall score (FACT-G) is the sum over the four subscales and ranges from 0 to 108. Patients also completed 12 questions related to prostate cancer, and the prostate subscale score is the sum of those responses (with some items reverse scored). Scores range from 0 to 48, and as with the other FACT subscales higher scores indicate better HRQOL. FACT-P is the sum of FACT-G and the prostate subscale. This questionnaire was added half-way through the study.</description>
        <time_frame>8 weeks</time_frame>
        <population>All participants who completed the FACT_P at any time.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm I - Placebo</title>
            <description>Patients receive oral placebo twice daily (total of 6 capsules per day).
Placebo: Given orally</description>
          </group>
          <group group_id="O2">
            <title>Arm II - Low Dose</title>
            <description>Patients receive oral L-arginine and oral placebo twice daily (total of 3 capsules of each per day).
Placebo: Given orally
Oral L-Arginine: Given orally 3 capsules ArginMax and 3 Placebo capsules</description>
          </group>
          <group group_id="O3">
            <title>Arm III - High Dose</title>
            <description>Oral L-arginine twice daily = 6 capsules per day.
Oral L-Arginine: Given orally 3 capsules ArginMax and 3 Placebo capsules
Oral L-Arginine: Patients will take 6 capsules of ArginMax twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Quality of Life</title>
          <description>Quality of life is quantified by the Functional Assessment of Cancer Therapy - Prostate (FACT_P) questionnaire. The FACT questionnaire is comprised of four subscales â€“ social, emotional, functional, and physical. Each subscale is obtained by summing over 6-7 items, each of which is coded on a 0 to 4 scale. Negatively worded questions are reverse scored and higher scores for each subscale indicate better HRQOL. The social, functional, and physical subscales range from 0 to 28 while the emotional subscale ranges from 0 to 24. The overall score (FACT-G) is the sum over the four subscales and ranges from 0 to 108. Patients also completed 12 questions related to prostate cancer, and the prostate subscale score is the sum of those responses (with some items reverse scored). Scores range from 0 to 48, and as with the other FACT subscales higher scores indicate better HRQOL. FACT-P is the sum of FACT-G and the prostate subscale. This questionnaire was added half-way through the study.</description>
          <population>All participants who completed the FACT_P at any time.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="26"/>
                <count group_id="O3" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="128.54" spread="3.11"/>
                    <measurement group_id="O2" value="128.67" spread="3.08"/>
                    <measurement group_id="O3" value="127.41" spread="3.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>8 weeks of treatment plus 4 weeks after treatment ends</time_frame>
      <desc>The sample size for this section was the number of participants in each arm who had post-randomization toxicity data recorded.</desc>
      <group_list>
        <group group_id="E1">
          <title>Arm I - Placebo</title>
          <description>Patients receive oral placebo twice daily (total of 6 capsules per day).
Placebo: Given orally</description>
        </group>
        <group group_id="E2">
          <title>Arm II - Low Dose</title>
          <description>Patients receive oral L-arginine and oral placebo twice daily (total of 3 capsules of each per day).
Placebo: Given orally
Oral L-Arginine: Given orally 3 capsules ArginMax and 3 Placebo capsules</description>
        </group>
        <group group_id="E3">
          <title>Arm III - High Dose</title>
          <description>Oral L-arginine twice daily = 6 capsules per day.
Oral L-Arginine: Given orally 3 capsules ArginMax and 3 Placebo capsules
Oral L-Arginine: Patients will take 6 capsules of ArginMax twice daily</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="42"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="42"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="41"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Gastrointestional Disorder - Other</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="42"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Agitation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Breast Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="41"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Hot Flashes</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infections and Infestations - Other</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Penile Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="42"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Hematuria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>urinary retention</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Ejaculation Disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="42"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Erectile Dysfunction</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Libido Increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Respiratory, thoracic and mediastinal disorder - other</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Bruising</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Rash maculo-papular</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Rash pustular</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Doug Case</name_or_title>
      <organization>Wake Forest NCORP Research Base</organization>
      <phone>(336) 716-1048</phone>
      <email>dcase@wakehealth.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

